Abstract
Objective: Temporomandibular disorder (TMD) is a very common and costly pain problem concerning the temporomandibular joint. A previous study has shown that for the treatment of acute myogenic TMD, TheraBite (R) (TB) offers a faster and greater effect than usual care consisting of physical therapy (PT). This study estimates the cost-effectiveness of TB compared to PT. Methods: Differences in costs and quality-adjusted life-years (QALYs) between TB and PT are analyzed using a decision model. Results: The point estimate for the incremental cost-effectiveness ratio is -28,068 EUR (-30,191 USD) per QALY (dominant) for TB versus PT. At the willingness-to-pay ratio of 20,000 EUR (21,513 USD) per QALY, TB has a 97% probability of being cost-effective compared to PT. Conclusion: TB is expected to be cost-effective compared to PT for the treatment of acute myogenic TMD, offering faster recovery of quality of life for patients, at a lower cost to society
| Original language | English |
|---|---|
| Pages (from-to) | 290-297 |
| Number of pages | 8 |
| Journal | Cranio |
| Volume | 35 |
| Issue number | 5 |
| Early online date | 2016 |
| DOIs | |
| Publication status | Published - 3 Sept 2017 |
Keywords
- cost-effectiveness
- mandibular function
- orofacial pain
- physical therapy
- quality of life
- Temporomandibular disorder
- TheraBite
- trismus
Fingerprint
Dive into the research topics of 'The cost-effectiveness of TheraBite (R) as treatment for acute myogenic temporomandibular disorder'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver